Pascal Deschatelets - 08 Jun 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Scientific Officer
Signature
/s/ David Watson, attorney-in-fact for Pascal Deschatelets
Issuer symbol
APLS
Transactions as of
08 Jun 2022
Net transactions value
-$479,685
Form type
4
Filing time
09 Jun 2022, 17:23:12 UTC
Previous filing
02 May 2022
Next filing
22 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $32,040 +12,000 +1.3% $2.67* 903,775 08 Jun 2022 Direct F1
transaction APLS Common Stock Sale $529,080 -12,000 -1.3% $44.09 891,775 08 Jun 2022 Direct F1
transaction APLS Common Stock Options Exercise $17,355 +6,500 +0.73% $2.67* 898,275 08 Jun 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -12,000 -3.3% $0.000000 352,999 08 Jun 2022 Common Stock 12,000 $2.67 Direct F1, F3
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -6,500 -1.8% $0.000000 346,499 08 Jun 2022 Common Stock 6,500 $2.67 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is a scheduled exercise and sale from a 10B5-1 trading plan.
F2 This is a scheduled exercise from 10B5-1 trading plan.
F3 This stock option was granted on 12/5/2013 and is fully vested.